Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 12/20 | 0.76 |
| ▸ | ADORA2B | P29275 | 10/20 | 0.76 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.67 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | RAB9A | P51151 | 1/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.65 |
| ▸ | PKM | P14618 | 1/20 | 0.65 |
| ▸ | HPGD | P15428 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.65 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5501004 | 1.00 | ADORA2A (0.76) | ADORA2AADORA2BADORA3ADORA1LMNA | |
| SCHEMBL5492996 | 0.86 | ADORA2A (1.00) | ADORA2AADORA2BADORA3ADORA1 | |
| SCHEMBL5493006 | 0.86 | ADORA2A (1.00) | ADORA2AADORA2BADORA3ADORA1 | |
| SCHEMBL5499179 | 0.86 | SLC29A1 (0.65) | ADORA2BADORA3ADORA1LMNARAB9A | |
| SCHEMBL11875079 | 0.82 | ADORA3 (0.69) | ADORA3LMNARAB9ACYP3A4PKM | |
| SCHEMBL11875046 | 0.82 | ADORA3 (0.69) | ADORA3LMNARAB9ACYP3A4PKM | |
| Bvt.115959 SCHEMBL5703538 | 0.81 | ADORA3 (0.84) | ADORA2AADORA2BADORA3ADORA1 | |
| SCHEMBL13863566 | 0.80 | ADORA3 (1.00) | ADORA2AADORA2BADORA3LMNA | |
| SCHEMBL3749420 | 0.80 | ADORA3 (1.00) | ADORA2AADORA2BADORA3LMNA | |
| SCHEMBL3749410 | 0.80 | ADORA3 (1.00) | ADORA2AADORA2BADORA3LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1446413-A4 | SYNTHESIS OF 2-ARALKOXY ADENOSINES AND 2-ALKOXYADENOSINES | KING PHARMACEUTICALS RES & DEV (US) | 2007-10-17 | — | — | EP | disclosed |
| US-6951932-B2 | Synthesis of 2-aralkoxyadenosines and 2-alkoxyadenosines | KING PHARMACEUTICALS RESEARCH & DEVELOPMENT, INC. (US) | 2005-10-04 | — | — | US | disclosed |
| EP-1446413-A1 | SYNTHESIS OF 2-ARALKOXY ADENOSINES AND 2-ALKOXYADENOSINES | King Pharmaceuticals Research and Development Inc. (US) | 2004-08-18 | — | — | EP | disclosed |
| US-20030199686-A1 | Synthesis of 2-aralkoxyadenosines and 2-alkoxyadenosines | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2003-10-23 | — | — | US | disclosed |
| WO-2003035662-A1 | SYNTHESIS OF 2-ARALKOXY ADENOSINES AND 2-ALKOXYADENOSINES | KING PHARMACEUTICALS RESEARCH & DEVELOPMENT, INC. (US) | 2003-05-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199686-A1 | Synthesis of 2-aralkoxyadenosines and 2-alkoxyadenosines | AMPD2, ADAR, ADA | ADORA2A 16/4885ADORA2B 58/4885ADORA3 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.